224178-67-0

Basic information

• Product Name: 4-(PIPERIDIN-4-YLOXY)BENZONITRILE
• Synonyms: 4-(PIPERIDIN-4-YLOXY)BENZONITRILE;4-(4-Cyanophenoxy)piperidine;3-Methoxy-4-(piperidin-4-yloxy)benzonitrile hydrochloride
• CAS NO: 224178-67-0
• Molecular Formula: C₁₂H₁₄N₂O
• Molecular Weight: 202.25
• Mol File: 224178-67-0.mol

Chemical Properties

• Boiling Point: 366.8 °C at 760mmHg
• Flash Point: 175.6 °C
• Appearance: /
• Density: 1.13
• Vapor Pressure: 1.43E-05mmHg at 25°C
• Refractive Index: 1.563
• CAS DataBase Reference: 4-(PIPERIDIN-4-YLOXY)BENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(PIPERIDIN-4-YLOXY)BENZONITRILE(224178-67-0)
• EPA Substance Registry System: 4-(PIPERIDIN-4-YLOXY)BENZONITRILE(224178-67-0)

Safety Data

• RIDADR: UN3439
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 224178-67-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(PIPERIDIN-4-YLOXY)BENZONITRILE is used as a building block for the synthesis of various pharmaceuticals due to its unique structure and properties that facilitate the creation of new drug molecules.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(PIPERIDIN-4-YLOXY)BENZONITRILE is utilized as a key intermediate in the development of agrochemicals, contributing to the production of effective and innovative products for crop protection and enhancement.
Used in Fine Chemicals Synthesis:
4-(PIPERIDIN-4-YLOXY)BENZONITRILE serves as a crucial component in the synthesis of fine chemicals, which are high-purity, specialty chemicals used in various industries, including fragrances, flavors, and other high-value applications.
Used in Organic Chemistry Research and Development:
As a valuable reagent, 4-(PIPERIDIN-4-YLOXY)BENZONITRILE is employed in organic chemistry research and development to explore new synthetic pathways, reactions, and the creation of novel chemical entities with potential applications in various fields.

InChI:InChI=1/C12H14N2O/c13-9-10-1-3-11(4-2-10)15-12-5-7-14-8-6-12/h1-4,12,14H,5-8H2

Upstream product

• 5382-16-1 4-HYDROXYPIPERIDINE 
• 1194-02-1 4-fluorobenzonitrile 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 118811-07-7 tert-butyl 4-(tosyloxy)piperidin-1-carboxylate 
• 767-00-0 4-cyanophenol 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 623-03-0 4-Cyanochlorobenzene 
• 333954-86-2 4-(4-cyano phenoxy)piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 397275-27-3 4-((1-cyclobutylpiperidin-4-yl)oxy)benzonitrile 
• 1394808-23-1 N-[4-(1-cyclobutylpiperidin-4-yloxy)benzyl]morpholine-4-ylamide 
• 1394808-77-5 4-(1-cyclobutyl piperidin-4-yloxy)benzylamine 
• 1356625-87-0 N-(1-(4-cyanobenzyl)piperidin-4-yl)-5-(4-(4-cyanophenoxy)piperidin-1-yl)picolinamide 

Relevant articles and documents

Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase

Multi-target inhibitors have become increasing popular as a means to leverage the advantages of poly-pharmacology while simplifying drug delivery. Here, we describe dual inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH), two targets known to synergize when treating inflammatory and neuropathic pain. The structure activity relationship (SAR) study described herein initially started with t-TUCB (trans-4-[4-(3-trifluoromethoxyphenyl-l-ureido)-cyclohexyloxy]-benzoic acid), a potent sEH inhibitor that was previously shown to weakly inhibit FAAH. Inhibitors with a 6-fold increase of FAAH potency while maintaining high sEH potency were developed by optimization. Interestingly, compared to most FAAH inhibitors that inhibit through time-dependent covalent modification, t-TUCB and related compounds appear to inhibit FAAH through a time-independent, competitive mechanism. These inhibitors are selective for FAAH over other serine hydrolases. In addition, FAAH inhibition by t-TUCB appears to be higher in human FAAH over other species; however, the new dual sEH/FAAH inhibitors have improved cross-species potency. These dual inhibitors may be useful for future studies in understanding the therapeutic application of dual sEH/FAAH inhibition.

INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH)

The present invention provides compounds that are dual inhibitors of soluble epoxide hydrolase and fatty acid amide hydrolase. The present invention also provides methods of using the compounds to inhibit soluble epoxide hydrolase and fatty acid amide hydrolase, and to treat cancer.

Tankyrase inhibitor

The invention belongs to the technical field of medicines and particularly relates to a tankyrase inhibitor represented by a general formula (I) shown in the description and pharmaceutically acceptable salts, esters, solvates or stereoisomers thereof, wherein R1, R2, R3, m, n, Z, L, Q, A, X1, X2 and Y are as defined in the description. The invention further relates to a preparation method for the compounds, pharmaceutical preparations and pharmaceutical compositions containing the compounds and application of the compound and the pharmaceutically acceptable salts, esters, solvates or stereoisomers thereof in preparation of drugs for treating and/or preventing tankyrase mediated cancers and related diseases.

NOVEL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS

The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pha

NOVEL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS

The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pha

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

4-Phenoxypiperidines: Potent, conformationally restricted, non-imidazole histamine H3 antagonists

Two new series of 4-(1-alkyl-piperidin-4-yloxy)-benzonitriles and 4-(1-isopropyl-piperidin-4-yloxy)-benzylamines have been prepared. In vitro activity was determined at the recombinant human H3 receptor and several members of these new series were found to be potent H3 antagonists. The present compounds contain a 4-phenoxypiperidine core, which behaves as a conformationally restricted version of the 3-amino-1-propanol moiety common to the many previously described non-imidazole histamine H 3 ligands. One selected member of the new series, 4-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-morpholine (13g), was found to be a potent, highly selective H3 receptor antagonist with in vivo efficacy in a rat EEG model of wakefulness at doses as low as 1 mg/kg sc.